Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater weight loss than GLP-1RAs alone (e.g., semaglutide) in both diabetic and non-diabetic populations, while potentially reducing nausea through GIP receptor signaling.
Tirzepatide (5-15 mg weekly) is more effective for weight loss than semaglutide in patients with type 2 diabetes, achieving 8.5-12.4% weight loss compared to 6.7% for semaglutide. It works by targeting both GIP and GLP-1 receptors, potentially offering a better side effect profile regarding nausea.
Tirzepatide has demonstrated significant weight loss effects in phase III clinical trials... Furthermore, tirzepatide has shown greater weight loss effects than the GLP-1RA semaglutide. In a clinical trial of patients with type 2 diabetes, weekly tirzepatide at 5, 10, or 15 mg for 40 weeks resulted in an 8.5–12.4% weight loss, compared to 6.7% with semaglutide at 1 mg/week [29].
Why this rating
Supported by multiple Phase III trials (SURPASS, SURMOUNT) with robust data.
Source
Comparing the anorexigenic effects and mechanisms of gut-derived GLP-1 and its receptor agonists: insights into incretin-based therapies for obesity
Yuta Masuda et al. · Diabetology International · 2025
DOI 10.1007/s13340-025-00819-9
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide induce significant weight loss (up to ~15%) in non-diabetic individuals with obesity, primarily by acting on GLP-1 receptors in the brain (specifically the arcuate nucleus and area postrema) to suppress food intake.Strong
- Endogenous gut-derived GLP-1, secreted in response to nutrients or non-caloric stimuli (like gastrointestinal distension), regulates feeding behavior and glucose metabolism via vagal sensory nerves without causing the adverse effects (nausea/vomiting) associated with GLP-1 receptor agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →